Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?
Objective: To investigate if polymorphisms of the HOMER1 and COMT gene are associated with psychosis in Parkinson’s disease (PD). Background: Psychosis is one of the…Mechanisms and Consequences of Weight Gain After Deep Brain Stimulation of the Subthalamic Nucleus in Patients with Parkinson’s Disease
Objective: To identify stimulation-dependent effects of deep brain stimulation (DBS) on body weight and energy metabolism depending on the electrode position within the subthalamic nucleus…Longitudinal predictors of quality of life in Parkinson’s disease: analysis of NILS cohort data at four years follow up
Objective: To analyze the change in quality of life (QoL) and its longitudinal predictors in a sample of Parkinson’s disease (PD) patients. Background: Natural progression…Non-apoptotic caspase-3 activation mediates early synaptic dysfunction of indirect pathway neurons in the parkinsonian striatum
Objective: We set out to investigate whether caspase-3 plays a role in the loss of dendritic spines and the concomitant synaptic deficits that develop in…Multimodal assessment of nigrostriatal degeneration in de novo Parkinson’s disease
Objective: To study nigrostriatal changes with a multifactorial neuroimaging approach in order to further characterize early abnormalities in Parkinson’s Disease (PD). Background: Imaging techniques allow…Quality of Life in African American and White Parkinson’s Disease Patients
Objective: To determine the quality of life of African American (AA) and White patients with Parkinson’s disease (PD) at the Rush University Medical Center (RUMC)…Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.
Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2
Objective: To determine whether the positive effects of prasinezumab on motor progression measured by Roche PD Mobile Application (PASADENA study Part 1; 0-52 weeks; NCT03100149)…Effect of CDNF in a novel combination stressor model of Parkinson’s disease
Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…A fully immersive virtual reality environment to study gait modulation in Parkinson’s disease
Objective: To investigate the safety and efficacy of a fully immersive virtual reality (VR) paradigm to study gait modulation in subjects with Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 341
- 342
- 343
- 344
- 345
- …
- 436
- Next Page »